Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01401829
Other study ID # ROG-SIU-11-004
Secondary ID
Status Terminated
Phase Phase 1
First received July 21, 2011
Last updated May 11, 2015
Start date July 2011
Est. completion date January 2013

Study information

Verified date May 2015
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

To determine if weekly exercise compared to stretching has an effect on fatigue, depression, and anxiety in endometrial cancer survivors.


Description:

Endometrial cancer is the most prevalent gynecologic cancer in women. Because of its excellent 5 year survival rate of 83%, addressing longer term cancer effects in this group is an important aspect of cancer survivor care. Unfortunately, women with a history of endometrial cancer may report persistent levels of fatigue, depression, and anxiety that are, on average, higher than those of healthy, gynecologic out-patients. Physical activity is one potential approach to reducing these symptoms, but little is known about the effects of physical activity in endometrial cancer survivors specifically. Furthermore, current evidence is insufficient to make recommendations regarding the optimal exercise amount, type, and duration for improving fatigue, depression, or anxiety after a cancer diagnosis (any cancer type).

This pilot, randomized trial is unique in its focus on endometrial cancer survivors, a previously understudied population with a large potential for benefiting from regular physical activity. Two separate walking intervention groups will work with an exercise specialist three times a week to walk for either 75 minutes (group 1) or 150 minutes (group 2) weekly. The participants will start out slowly and then gradually increase to the particular group goal of 75 or 150 minutes. The stretching exercise group will work with an exercise specialist doing stretching/flexibility exercises three times a week starting with 15 seconds and then gradually increasing to 30 seconds of holding the stretch.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date January 2013
Est. primary completion date January 2013
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- 1) Female, 18 to 70 years of age with history of Stage I, II, or III endometrial cancer diagnosis occurring at least 6 months prior to study enrollment,

- 2) if chemotherapy or radiation therapy was received, patient must be = 4 weeks post final primary treatment administration,

- 3) if patient has undergone surgical procedure, must be = 8 weeks post-procedure or cleared by surgeon for moderate intensity walking,

- 4) English speaking,

- 5) medical clearance for participation provided by primary care physician or oncologist,

- 6) average fatigue over the past week of =3 on a 1 to 10 Likert scale or worrying thoughts = a lot of the time or enjoy the things they used to a little/ not at all.

Exclusion Criteria:

- 1) metastatic or recurrent endometrial cancer,

- 2) inability to ambulate without assistance,

- 3) unstable angina,

- 4) New York Heart Association class II, III, or IV congestive heart failure,

- 5) uncontrolled asthma,

- 6) having been told by a physician to only do exercise prescribed by a physician,

- 7) dementia or organic brain syndrome,

- 8) schizophrenia or active psychosis,

- 9) participating, on average, in more than 20 minutes of physical activity on two or more days per week during the past six months,

- 10) anticipates undergoing elective surgery during the duration of the intervention which would interfere with the intervention participation,

- 11) does not live or work less than 50 miles from the study site,

- 12) lack of transportation to the study site,

- 13) plans to move residence out of the local area during the study duration,

- 14) plans to travel out of the local area for more than a week during the intervention,

- 15) contraindication to participation in physical activity,

- 16) non-compliant with sleep apnea treatments.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Behavioral:
150 weekly minutes walking
12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
75 weekly minutes walking
12 week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
Stretching/Flexibility exercise
12 week stretching intervention group with a goal of 3 sessions per week while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety

Locations

Country Name City State
United States Southern Illinois University School of Medicine Springfield Illinois

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

References & Publications (6)

Rogers LQ, Courneya KS, Robbins KT, Rao K, Malone J, Seiz A, Reminger S, Markwell SJ, Burra V. Factors associated with fatigue, sleep, and cognitive function among patients with head and neck cancer. Head Neck. 2008 Oct;30(10):1310-7. doi: 10.1002/hed.20873. — View Citation

Rogers LQ, Hopkins-Price P, Vicari S, Markwell S, Pamenter R, Courneya KS, Hoelzer K, Naritoku C, Edson B, Jones L, Dunnington G, Verhulst S. Physical activity and health outcomes three months after completing a physical activity behavior change intervention: persistent and delayed effects. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1410-8. doi: 10.1158/1055-9965.EPI-08-1045. Epub 2009 Apr 21. — View Citation

Rogers LQ, Malone J, Rao K, Courneya KS, Fogleman A, Tippey A, Markwell SJ, Robbins KT. Exercise preferences among patients with head and neck cancer: prevalence and associations with quality of life, symptom severity, depression, and rural residence. Head Neck. 2009 Aug;31(8):994-1005. doi: 10.1002/hed.21053. — View Citation

Rogers LQ, Markwell S, Hopkins-Price P, Vicari S, Courneya KS, Hoelzer K, Verhulst S. Reduced barriers mediated physical activity maintenance among breast cancer survivors. J Sport Exerc Psychol. 2011 Apr;33(2):235-54. — View Citation

Rogers LQ, Markwell SJ, Courneya KS, McAuley E, Verhulst S. Exercise preference patterns, resources, and environment among rural breast cancer survivors. J Rural Health. 2009 Fall;25(4):388-91. doi: 10.1111/j.1748-0361.2009.00249.x. — View Citation

Rogers LQ. Objective monitoring of physical activity after a cancer diagnosis: challenges and opportunities for enhancing cancer control. Phys Ther Rev. 2010 Jun 1;15(3):224-237. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary fatigue 13-item multi-dimensional fatigue scale [i.e. Fatigue Symptom Inventory (FACT-F)] Change from baseline at 12 weeks No
Secondary Depression and Anxiety 14 item Hospital Anxiety and Depression Scale (PROMIS) Change from baseline at 8 weeks No
Secondary Depression and Anxiety 14 item Hospital Anxiety and Depression Scale (PROMIS) Change in baseline at 12 weeks No
Secondary Task self-efficacy 4 item scale for chronic disease patients Change in baseline at 8 weeks No
Secondary Task self-efficacy 4 item scale for chronic disease patients Change in baseline at 12 weeks No
Secondary Quality of Life Functional Assessment of Cancer Therapy-Endometrial and the Satisfaction With Life Scale Change in baseline at 8 weeks No
Secondary Quality of Life Functional Assessment of Cancer Therapy-Endometrial and the Satisfaction With Life Scale Change in baseline at 12 weeks No
Secondary Body Mass Index (BMI) BMI calculated with weight and height Change in baseline at 8 weeks No
Secondary Body Mass Index (BMI) BMI calculated with weight and height Change in baseline at 12 weeks No
Secondary Body Composition Bioelectrical Impedance Change in baseline at 8 weeks No
Secondary Body Composition Bioelectrical Impedance Change in baseline at 12 weeks No
Secondary Waist and Hip circumferences the average of three measures of waist and hip (each) using a tape measure Change in baseline at 8 weeks No
Secondary Waist and Hip circumferences the average of three measures of waist and hip (each) using a tape measure Change in baseline at 12 weeks No
Secondary fitness submaximal fitness test Change in baseline at 8 weeks No
Secondary fitness submaximal fitness test Change in baseline at 12 weeks No
Secondary muscle strength back/leg dynamometer and hand grip dynamometer Change in baseline at 8 weeks No
Secondary muscle strength back/leg dynamometer and hand grip dynamometer Change in baseline at 12 weeks No
Secondary feasibility Number of patients recruited, Number of patients who complete the walking intervention, Number of adverse events reported, and Number of patients who complete the study one year Yes
Secondary demographic, lifestyle, and medical covariates self-administered survey one year No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05796518 - Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors N/A
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06463028 - Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Completed NCT03820024 - MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback N/A
Active, not recruiting NCT05082025 - Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Phase 2
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer
Completed NCT05378152 - Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity N/A
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Recruiting NCT04569773 - Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Not yet recruiting NCT06366347 - ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab Phase 2
Not yet recruiting NCT05998798 - Revealing Engagement Patterns Among Endometrial Cancer Patients
Not yet recruiting NCT06073184 - Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium Phase 2
Terminated NCT02907073 - Positron Emission Tomography (PET) Imaging Studies With NIS Reporter Phase 1/Phase 2
Completed NCT02413606 - ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More? N/A